William Blair Estimates Amgen’s Q1 Earnings (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) – Research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Amgen in a report issued on Wednesday, March 5th. William Blair analyst M. Phipps forecasts that the medical research company will post earnings of $4.42 per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share. William Blair also issued estimates for Amgen’s Q2 2026 earnings at $5.00 EPS and Q3 2026 earnings at $5.24 EPS.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%.

Other research analysts also recently issued reports about the company. Redburn Partners reduced their target price on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. UBS Group reaffirmed a “hold” rating on shares of Amgen in a research note on Wednesday, February 12th. Wolfe Research assumed coverage on Amgen in a research note on Friday, November 15th. They set a “peer perform” rating for the company. Deutsche Bank Aktiengesellschaft reduced their target price on Amgen from $305.00 to $285.00 in a research note on Wednesday, November 27th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $380.00 target price on shares of Amgen in a research note on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $314.95.

Amgen Trading Up 2.2 %

Shares of AMGN stock opened at $324.86 on Friday. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The company has a market cap of $174.52 billion, a price-to-earnings ratio of 43.03, a PEG ratio of 2.63 and a beta of 0.56. The stock has a 50 day simple moving average of $286.14 and a 200-day simple moving average of $299.89. Amgen has a 1-year low of $253.30 and a 1-year high of $346.85.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 2.93%. The ex-dividend date is Friday, May 16th. Amgen’s payout ratio is currently 126.09%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $293.12, for a total value of $7,341,190.40. Following the transaction, the executive vice president now owns 28,987 shares of the company’s stock, valued at approximately $8,496,669.44. This represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock worth $20,644,335 in the last three months. 0.69% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Amgen

Several hedge funds have recently bought and sold shares of the company. Swedbank AB lifted its stake in Amgen by 1.1% during the third quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock worth $173,639,000 after purchasing an additional 5,751 shares during the last quarter. Beacon Financial Advisory LLC increased its position in Amgen by 4.6% during the third quarter. Beacon Financial Advisory LLC now owns 769 shares of the medical research company’s stock worth $248,000 after buying an additional 34 shares during the period. M&G PLC increased its position in Amgen by 676.5% during the third quarter. M&G PLC now owns 283,017 shares of the medical research company’s stock worth $91,131,000 after buying an additional 246,568 shares during the period. Graypoint LLC increased its position in Amgen by 3.0% during the third quarter. Graypoint LLC now owns 5,164 shares of the medical research company’s stock worth $1,664,000 after buying an additional 148 shares during the period. Finally, Advisor Resource Council acquired a new position in Amgen during the third quarter worth approximately $630,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.